Link to AVISE PG
Link to Avise Test Procedure
Link to FAQs

AVISE MCV

Printer friendly version (pdf)

From Speculation to Confirmation in early RA

A sensitive and specific test that improves upon traditional means of diagnosing rheumatoid arthritis (RA).

AVISE MCV detects autoantibodies to mutated citrullinated vimentin (MCV). MCV is a naturally occurring protein isoform that is found within the inflamed synovium of patients with RA, whereas other citrullinated peptide markers use a synthetic antigen composition [1].

AVISE MCV detects autoantibodies to mutated citrullinated vimentin

Avise MCV is a useful adjunct to traditional clinical and laboratory methods for diagnosing RA. Several studies have established the clinical performance of anti-MCV in diagnosing RA. The clinical performance of anti-MCV versus anti-CCP across eight peer reviewed studies can be summarized as follows:

MCV vs. CCP

* Studies included anti-CCP tests from multiple manufacturers and generations: anti-CCP2 and anti-CCP3.1.

The Avise MCV test offers a high level of diagnostic accuracy as well as helps to identify patients who are likely to have more severe disease progression [2]. Graphs below illustrate the difference over a five year period in two common clinical parameters of RA patients who are positive versus negative at baseline.

The Avise MCV test offers a high level of diagnostic accuracy

Avise MCV has a unique diagnostic spectrum, meaning that it will be positive even in a certain percentage of patients who are negative for both anti-CCP and RF. The diagram below illustrates the findings from one study where 10% of early RA patients were positive for Avise MCV, but negative for RF and anti-CCP. [9]

Diagram of Lab Marker Sensitivity

Diagram of Lab Marker Sensitivity

(n=470; Sensitivity in patients who developed RA within an inception cohort of undifferentiated arthritis patients) [9]. The sensitivity for Anti-MCV, Anti-CCP2, and RF in this study was 63%, 53% and 48% respectively.

Early diagnosis and appropriate treatment of rheumatoid arthritis are critically important to prevent erosive joint destruction and disability. Anti-MCV testing provides the potential to better detect patients who have RA and identify those likely to experience more severe disease progression.

Results from the Avise MCV test are provided on a color graph to facilitate easy interpretation and dialogue with patients. Below is an example of the test report.

Avise MCV test result form

References:

  1. Bang H et al. Arthritis Rheum 2007; 56(8):2503-2511. (review abstract)
  2. Mathsson L et al. Arthritis Rheum. 2008; 58(1):36-45. (review abstract)
  3. Innala L et al. J Rheumatol. 2008;35(6):1002-1008. (review abstract)
  4. Ursum J et al. Arthritis Res Ther. 2008; 10(1):R12. (review abstract)
  5. Dejaco C et al. Arthritis Res Ther. 2006; 8(4):R119. (review abstract)
  6. Bizzaro N et al. Clin Chem 2007; 53(8):1527-1533. (review abstract)
  7. Coenen D et al. Clin Chem 2007; 53(3):498-504. (review abstract)
  8. Soos L et al. J Rheumatol 2007; 34(8):1658-1663. (review abstract)
  9. Cypress Bioscience, Inc. Data on file.